Skip to content

A phase II study of preoperative stereotactic radiation therapy boost combined with short-course immunotherapy (pembrolizumab versus placebo, randomized, double-blind) and standard chemotherapy in patients with newly diagnosed HER2-negative non-metastatic breast cancer with lack of early metabolic response in 18-fluorodeoxyglucoseFDG-PET/CT after 1st chemoterapy cycle

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-504145-31-00
Acronym
BREAST-BOOSTER
Enrollment
78
Registered
2023-06-26
Start date
2024-06-10
Completion date
Unknown
Last updated
2024-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2 negative breast cancer

Brief summary

Histopathological confirmation in the postoperative material of complete tumor regression after preoperative systemic treatment (pCR), defined as the absence of invasive tumor tissue in the breast and regional lymph nodes (AJCC/UICC definition, allows residual DCIS tissue as pCR ypT0/is N0)

Detailed description

Assessment of complete regression in the postoperative histopathological examination in the population of all 78 patients receiving preoperative chemotherapy and radiotherapy. The presence of pCR in more than 13 patients out of a group of 78 enrolled and receiving chemotherapy and radiotherapy will be treated as fulfillment of the secondary endpoint criterion, Evaluation of response to preoperative treatment by evaluating postoperative material in histopathological examination according to the RCB (Residual Cancer Burden) protocol, comparing the group treated with pembrolizumab with radiotherapy to the group treated with placebo and radiotherapy, by comparing the numerical RCB ratio between both groups, Assessment of time to recurrence of invasive cancer - (Invasive Disease Free Survival, IDFS), comparison of the group treated with pembrolizumab with radiotherapy to the group treated with placebo + radiotherapy (according to Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System, Hudis et al. Journal of Clinical Oncology 2007), Comparison of quality of life - general health status based on the QL2 scale of the EORTC QLQ-C30 questionnaire of the group treated with pembrolizumab with radiotherapy to the group treated with placebo and radiotherapy

Interventions

DRUGPaclitaxelum Accord
DRUGCarbomedac
DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

Sponsors

Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Histopathological confirmation in the postoperative material of complete tumor regression after preoperative systemic treatment (pCR), defined as the absence of invasive tumor tissue in the breast and regional lymph nodes (AJCC/UICC definition, allows residual DCIS tissue as pCR ypT0/is N0)

Secondary

MeasureTime frame
Assessment of complete regression in the postoperative histopathological examination in the population of all 78 patients receiving preoperative chemotherapy and radiotherapy. The presence of pCR in more than 13 patients out of a group of 78 enrolled and receiving chemotherapy and radiotherapy will be treated as fulfillment of the secondary endpoint criterion, Evaluation of response to preoperative treatment by evaluating postoperative material in histopathological examination according to the RCB (Residual Cancer Burden) protocol, comparing the group treated with pembrolizumab with radiotherapy to the group treated with placebo and radiotherapy, by comparing the numerical RCB ratio between both groups, Assessment of time to recurrence of invasive cancer - (Invasive Disease Free Survival, IDFS), comparison of the group treated with pembrolizumab with radiotherapy to the group treated with placebo + radiotherapy (according to Proposal for Standardized Definitions for Efficacy End Points

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026